Certara (CERT) Competitors

$16.08
-0.39 (-2.37%)
(As of 05/17/2024 08:53 PM ET)

CERT vs. NARI, PGNY, MRUS, GDRX, BHC, MLTX, CLDX, MRVI, FTRE, and ACLX

Should you be buying Certara stock or one of its competitors? The main competitors of Certara include Inari Medical (NARI), Progyny (PGNY), Merus (MRUS), GoodRx (GDRX), Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), Celldex Therapeutics (CLDX), Maravai LifeSciences (MRVI), Fortrea (FTRE), and Arcellx (ACLX). These companies are all part of the "medical" sector.

Certara vs.

Certara (NASDAQ:CERT) and Inari Medical (NASDAQ:NARI) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Inari Medical has higher revenue and earnings than Certara. Inari Medical is trading at a lower price-to-earnings ratio than Certara, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Certara$354.34M7.30-$55.36M-$0.39-41.23
Inari Medical$493.63M5.39-$1.64M-$0.41-111.59

74.0% of Certara shares are held by institutional investors. Comparatively, 91.0% of Inari Medical shares are held by institutional investors. 2.4% of Certara shares are held by insiders. Comparatively, 10.6% of Inari Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Inari Medical had 28 more articles in the media than Certara. MarketBeat recorded 30 mentions for Inari Medical and 2 mentions for Certara. Certara's average media sentiment score of 1.14 beat Inari Medical's score of 0.17 indicating that Certara is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Certara
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inari Medical
10 Very Positive mention(s)
2 Positive mention(s)
14 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Certara has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Inari Medical has a net margin of -4.54% compared to Certara's net margin of -17.02%. Certara's return on equity of 4.08% beat Inari Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Certara-17.02% 4.08% 2.79%
Inari Medical -4.54%-1.65%-1.23%

Inari Medical received 36 more outperform votes than Certara when rated by MarketBeat users. Likewise, 68.24% of users gave Inari Medical an outperform vote while only 34.92% of users gave Certara an outperform vote.

CompanyUnderperformOutperform
CertaraOutperform Votes
22
34.92%
Underperform Votes
41
65.08%
Inari MedicalOutperform Votes
58
68.24%
Underperform Votes
27
31.76%

Certara presently has a consensus target price of $20.06, indicating a potential upside of 24.77%. Inari Medical has a consensus target price of $65.71, indicating a potential upside of 43.64%. Given Inari Medical's stronger consensus rating and higher possible upside, analysts clearly believe Inari Medical is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Certara
0 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.36
Inari Medical
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

Inari Medical beats Certara on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERT vs. The Competition

MetricCertaraPrepackaged software IndustryMedical SectorNASDAQ Exchange
Market Cap$2.59B$22.13B$5.23B$7.98B
Dividend YieldN/A2.03%44.24%3.91%
P/E Ratio-41.2371.47126.7917.23
Price / Sales7.3010.832,373.9285.85
Price / Cash16.9969.5436.8831.98
Price / Book2.459.505.504.64
Net Income-$55.36M$368.67M$105.95M$217.28M
7 Day Performance-5.41%2.77%1.42%2.90%
1 Month Performance0.94%6.76%4.96%6.66%
1 Year Performance-20.00%18.31%7.89%9.89%

Certara Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NARI
Inari Medical
3.365 of 5 stars
$45.50
-0.2%
$65.71
+44.4%
-26.4%$2.65B$493.63M-110.981,300Insider Selling
PGNY
Progyny
4.1828 of 5 stars
$27.48
+0.3%
$44.11
+60.5%
-24.3%$2.63B$1.11B45.05563Analyst Forecast
MRUS
Merus
2.7986 of 5 stars
$44.77
-2.4%
$56.33
+25.8%
+103.9%$2.63B$38.34M-16.16172
GDRX
GoodRx
2.8218 of 5 stars
$6.65
-0.7%
$8.78
+32.0%
+47.2%$2.63B$750.27M-664.34694
BHC
Bausch Health Companies
3.8084 of 5 stars
$7.12
-0.1%
$11.33
+59.2%
-18.4%$2.61B$8.97B-5.7420,270
MLTX
MoonLake Immunotherapeutics
2.5804 of 5 stars
$40.77
-2.3%
$74.46
+82.6%
+44.3%$2.60BN/A-54.3650Analyst Forecast
CLDX
Celldex Therapeutics
0.7997 of 5 stars
$39.47
-1.6%
$66.00
+67.2%
+16.2%$2.60B$6.88M-13.85160
MRVI
Maravai LifeSciences
2.4057 of 5 stars
$10.70
+1.6%
$11.44
+7.0%
-15.4%$2.69B$288.95M-10.81650
FTRE
Fortrea
3.03 of 5 stars
$28.84
+2.6%
$35.57
+23.3%
N/A$2.58B$3.11B0.0018,000Earnings Report
High Trading Volume
ACLX
Arcellx
3.0044 of 5 stars
$50.62
+1.7%
$78.64
+55.3%
+29.5%$2.71B$110.32M-49.15130

Related Companies and Tools

This page (NASDAQ:CERT) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners